Impacting global healthcare with rapid, easy to use, point-of-care tests.

Rapid Pathogen Screening, Inc. (RPS) is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. RPS products are developed using a unique and innovative patented technology platform which the company can utilize to develop a variety of cost-effective tests.

RPS tests allow healthcare providers to more accurately diagnose diseases, provide appropriate and timely treatment, and reduce healthcare costs associated with spread of disease and unnecessary treatment methods.

Right Diagnosis. Right Treatment. Right Now.